The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders (Q40906180)

24 September 2017

1 reference

title

The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders (English)

1 reference

24 September 2017

1

van der Meché FG

1 reference

24 September 2017

van Doorn PA

2

1 reference

24 September 2017

publication date

1 February 1997

1 reference

24 September 2017

1 reference

24 September 2017

volume

20

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

136-147

1 reference

Inclusion body myositis: treatment with intravenous immunoglobulin.

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

The use of intravenous immunoglobulin in Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Multifocal motor neuropathy with conduction block: a study of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

The use of intravenous immune globulin in immunodeficiency diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Multifocal motor neuropathy: response to human immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Manipulating the Immune System with Immune Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Neurologic aspects of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous immunoglobulin in the treatment of Guillain-Barr� syndrome: a preliminary open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Successful treatment of neuropathies in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Multifocal motor neuropathy with conduction block: is it a distinct clinical entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Anti‐GM1 IgG antibodies and campylobacter bacteria in Guillain‐Barré syndrome: Evidence of molecular mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Experience with intravenous immunoglobulin in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous immunoglobulin in the management of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Treatment of myasthenia gravis with high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous immunoglobulin in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous gammaglobulin for myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Immunosuppressive treatment in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Intravenous immunoglobulin for multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Treatment of Guillain-Barré syndrome with high-dose gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Treatment of dermatomyositis with intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Multifocal demyelinating neuropathy with persistent conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Dutch Guillain-Barré Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

High dose immunoglobulin therapy is effective in the Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference